Stefanie Srock

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

Michael Herold, Antje Haas, Stefanie Srock et al. · Journal of Clinical Oncology · 2007 · 504 citations

Medicine, Hematology, Pharmacotherapy +17

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Gϋnter von Minckwitz, Fabio Puglisi, Javier Cortés et al. · The Lancet Oncology · 2014 · 146 citations

Medicine, Oncology, Pharmacotherapy +17

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Joseph Gligorov, Dinesh Doval, José Bines et al. · The Lancet Oncology · 2014 · 127 citations

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

Aysegül Ilhan‐Mutlu, Matthias Osswald, Yunxiang Liao et al. · Molecular Cancer Therapeutics · 2016 · 122 citations · Full text

Medicine, Oncology, Pharmacology +17

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

Axel Grothey, Josep Tabernero, Dirk Arnold et al. · Annals of Oncology · 2018 · 103 citations · Full text

Medicine, Oncology, Pharmacology +13